631909-08-5

Basic information

• Product Name: 3-bromo-N-methoxy-N,2-dimethylbenzamide
• Synonyms: 3-bromo-N-methoxy-N,2-dimethylbenzamide
• CAS NO: 631909-08-5
• Molecular Weight: 258.115
• Mol File: 631909-08-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 3-bromo-N-methoxy-N,2-dimethylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-N-methoxy-N,2-dimethylbenzamide(631909-08-5)
• EPA Substance Registry System: 3-bromo-N-methoxy-N,2-dimethylbenzamide(631909-08-5)

Safety Data

• Hazardous Substances Data: 631909-08-5(Hazardous Substances Data)

Upstream product

• 1117-97-1 N,0-dimethylhydroxylamine 
• 76006-33-2 3-bromo-2-methylbenzoic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 1373938-28-3 N-(5-(3-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2,6-difluorobenzamide 
• 1373939-99-1 5,5-dimethyl-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoxazol-4(5H)-one 
• 52779-76-7 1-(3-bromo-2-methylphenyl)ethan-1-one 
• 638215-10-8 ethyl [(4-{[1-(3-bromo-2-methylphenyl)pentyl]oxy}-2-methylphenyl)oxy]acetate 
• 638215-09-5 1-(3-bromo-2-methylphenyl)-1-pentanol 
• 83647-40-9 3-bromo-2-methylbenzaldehyde 
• 638215-08-4 1-(3-bromo-2-methylphenyl)-1-pentanone 

Relevant articles and documents

Discovery of a Novel Potent and Selective Calcium Release-Activated Calcium Channel Inhibitor: 2,6-Difluoro- N-(2′-methyl-3′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)benzamide. Structure-Activity Relationship and Preclinical Characterization

The role of calcium release-activated calcium (CRAC) channels is well characterized and is of particular importance in T-cell function. CRAC channels are involved in the pathogenesis of several autoimmune diseases, making it an attractive therapeutic target for treating inflammatory diseases, like rheumatoid arthritis (RA). A systematic structure-activity relationship study with the goal of optimizing lipophilicity successfully yielded two lead compounds, 36 and 37. Both compounds showed decent potency and selectivity and a remarkable pharmacokinetic profile. Further characterization in in vivo RA models and subsequent histopathological evaluation of tissues led to the identification of 36 as a clinical candidate. Compound 36 displayed an excellent safety profile and had a sufficient safety margin to qualify it for use in human testing. Oral administration of 36 in Phase 1 clinical study in healthy volunteers established favorable safety, tolerability, and good target engagement as measured by levels of IL-2 and TNF-α.

Aromatic ring-containing compound and application thereof

The present invention discloses an aromatic ring-containing compound and an application thereof, and provides an aromatic ring-containing compound represented by formula I, and a pharmaceutically acceptable salt, a hydrate, a solvate, a metabolite, a ster

Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.